Michelle Beck - Palomar College

Kevin A. Kelliher – Page 2
• Authored/co-authored multiple product applications, including four FDA approvals and first diagnostic device
approval for use as a primary screen for testing cervical cancer-causing virus.
• Led both internal team and external alliances for strategies toward manufacturing modifications to three approved
Digene products in conjunction with external partners.
• Provided final authorization for commercialization and post-commercialization activities, such as advertisement,
safety monitoring, and Digene company website content.
QUINTILES, INC., Rockville, MD 1998 – 2001
Assistant, Specialist, Senior Specialist
• Lead project manager on approved 2 BLAs and 1 NDA filing.
• Implemented and managed pivotal clinical Phase III project with budget exceeding $9M for approved NDA.
• Provided final review of non-clinical and clinical study reports for client submissions to FDA.
LAB OF GENETICS, NAT’L CANCER INSTIT., NAT’L INSTIT. OF HEALTH, Rockville, MD 1996 – 1998
Fellow
• Recipient of a two-year stipend awarded to a limited number of undergraduate candidates to perform biomedical
research fellowship under NIH scientists.
• Examined the role of immunoglobulin and c-myc chromosomal translocations in the development of murine plasmacytoma
as a model for human lymphoma through biochemical and molecular biological techniques, leading to correlating genetic
distinctions between resistant and sensitive lines in their ability to repair DNA damage caused by oxidative stress.
BOARD MEMBERSHIPS
KELLOGG VENTURE COMMUNITY, Evanston, IL 2010 - Present
Fundraising Committee Lead
• Serve as a KVC Board Member in supporting Kellogg students and alumni with launching successful business
ventures by fostering relationships between entrepreneurs, venture and equity sponsors.
• Facilitate raising in-kind donation for 2011 of projection of $3M.
• Support 113 mentors, 4,000 community members, and 184 businesses throughout Kellogg satellite campuses.
PUBLICATIONS
• Felix K, Kelliher K, Bornkamm GW and Janz S. Association of elevated mutagenesis in the spleen with genetic
susceptibility to induced plasmacytoma development in mice. Cancer Research, 1998; 58:1616-1619.
• Felix K, Kelliher K, Bornkamm G-W and Janz S. Elevated mutant frequencies in lymphoid tissues persist
throughout plasmacytoma development in BALB/c.8LIZ Mice. Cancer Research, 59:3621-3626.
• Felix K, Kelliher K, Bornkamm GW and Janz S. Transgenic shuttle vector assays for assessing oxidative B-cell
mutagenesis in vivo. In: Melchers F, Potter M, editors. Mechanisms of B Cell Neoplasia: Current Topics in
Microbiology and Immunology. Berlin, Heidelberg: Springer-Verlag; 246:369-377.
• Felix K, Kovalchuk AL, Park SS, Coleman AE, Ramsay ES, Qian M, Kelliher KA, Jones GM, Ried T, Bornkamm
GW and Janz S. Inducible mutagenesis in TEPC 2372, a mouse plasmacytoma cell line that harbors the transgenic
shuttle vector lLIZ. Mutation Research; 63:1712-1717.
• Rosenberg DW, Delker DA, Kelliher K and Bammler T. Glutathione S-transferase profiles in inbred mice:
Correlation with colon tumor susceptibility. University of Connecticut, Storrs, CT and University of Washington,
Seattle, WA. Abstract presented at American Association for Cancer Research, April 1996.